Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.
Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
J Allergy Clin Immunol Pract. 2021 Nov;9(11):4117-4129.e2. doi: 10.1016/j.jaip.2021.06.037. Epub 2021 Jul 12.
Although chronic rhinosinusitis with nasal polyps is a common inflammatory condition with significant morbidity and financial cost, information regarding prevalence and disease burden of this condition is scarce.
In this study, we determined nasal polyp prevalence, polyp grade, concomitant disease, and symptom burden in more than 10,000 central European subjects.
In this retrospective, cross-sectional study, 10,259 patients who had undergone routine examination of their nose by nasal endoscopy during a visit at a publicly accessible ear, nose, throat outpatient facility in Vienna were included. Patient details including presenting complaint, nasal symptoms, polyp score, age, gender, treatment, asthma, and allergic status were extracted retrospectively. A detailed questionnaire including history of nasal symptoms, Sino-Nasal Outcome Test-20 German Adapted Version, and visual analog scale was available for 101 patients with nasal polyps.
Nasal polyps were detected in 189 of the 10,259 (1.84%) patients. The calculated prevalence of polyps in Austria, adjusted for age and gender, was 1.95%. The average total polyp score (TPS) was 3.4, and 72.5% had a TPS of ≤4, with males and asthmatics having significantly larger polyps. Questionnaire analysis revealed that 67% suffered from a low symptom burden of ≤36. According to current European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) guidelines, 6% of patients with polyps met and another 8% potentially fulfilled the eligibility criteria for biological therapy.
Nasal polyp prevalence was calculated to be 1.95% of the Austrian population. Large polyps (TPS >4) were found in 25%, 33% suffered from a high nasal symptom burden, and between 6% and 14% of patients with polyps would be eligible for biological therapy according to EPOS guidelines.
尽管慢性鼻-鼻窦炎伴鼻息肉是一种常见的具有显著发病率和经济成本的炎症性疾病，但有关该疾病的流行情况和疾病负担的信息却很少。
本研究旨在确定 10000 多名中欧人群中鼻息肉的流行率、息肉分级、并存疾病和症状负担。
在这项回顾性、横断面研究中，纳入了 10259 名在维也纳一家公共耳鼻喉科门诊接受鼻内窥镜常规检查的患者。回顾性提取患者详细信息，包括就诊主诉、鼻部症状、息肉评分、年龄、性别、治疗方法、哮喘和过敏状态。101 例鼻息肉患者还可提供详细的问卷调查，包括鼻部症状史、Sino-Nasal Outcome Test-20 德国修订版和视觉模拟评分。
在 10259 例患者中，有 189 例（1.84%）患者检测到鼻息肉。经年龄和性别校正后，奥地利鼻息肉的计算患病率为 1.95%。平均总息肉评分（TPS）为 3.4，72.5%的患者 TPS≤4，男性和哮喘患者的息肉明显更大。问卷调查分析显示，67%的患者症状负担低（≤36）。根据目前的《欧洲鼻-鼻窦炎和鼻息肉诊疗指南》（EPOS），6%的鼻息肉患者符合生物治疗标准，另有 8%可能符合标准。
计算得出奥地利人群的鼻息肉患病率为 1.95%。大息肉（TPS>4）占 25%，33%的患者有高的鼻部症状负担，根据 EPOS 指南，6%至 14%的鼻息肉患者可能符合生物治疗标准。
